Abstract: The invention is directed to compositions comprising a modified dextran and to uses thereof for the treatment of wounds in a subject or for delivering a protein, an olignonucleotide, a pharmaceutical agent, or a mixture thereof to a subject. The modified dextran in the compositions can form hydrogels via crosslinking.

Abstract: The invention is directed to extracellular matrix replacement (EMR)-drug conjugates, EMR-fluorescent label conjugates, EMR-cell compositions; to methods of making the EMR-drug conjugates, EMR-fluorescent label conjugates, or EMR-cell compositions; to pharmaceutical compositions comprising the EMR-drug conjugates, EMR-fluorescent label conjugates, or EMR-cell combinations; and to methods of treating wounds using the EMR-drug conjugates, EMR-fluorescent label conjugates, or EMR-cell compositions. The invention is also directed to cure-in-place (CIP) EMRs, to methods of making the CIP EMRs, to pharmaceutical compositions comprising the CIP EMRs, and methods of treating wounds using the CIP EMRs.

Abstract: The present invention provides a method for the synthesis of ?2-amino acids. The method also provides methods yielding ?-substituted ?-amino aldehydes and ?-substituted ?-amino alcohols. The present method according to this invention allows for increased yield and easier purification using minimal chromatography or crystallization. The methods described herein are based on an aldehyde aminomethylation which involves a Mannich reaction between an aldehyde and a formaldehyde-derived N,O-acetal (iminium precursor) and a catalyst, such as, for example, L-proline or a pyrrolidine. The invention allows for large scale, commercial preparation of ?2-amino acids.

Abstract: Disclosed are beta-polypeptides that mimic the coiled-coil regions of gB and gH by display of the key hydrophobic residues for coiled-coil packing along one face of beta-polypeptide 12-helix. The most potent inhibitor blocks infection of CMV with an IC50 of approximately 20 m.